Loading...
AELIS
XPAR
Market cap11mUSD
Nov 20, Last price  
0.77EUR
1D
-3.50%
1Q
-27.17%
IPO
-93.57%
Name

Aelis Farma SA

Chart & performance

D1W1MN
XPAR:AELIS chart
P/E
—
P/S
5.08
EPS
—
Vol. 1Y
79.62%
Shs. 5Y
7.40%
Rev. 5Y
12.88%
Div Yld LY
—
Div Yld TTM
—
Revenues
2m
-22.18%
85,47239,9588,8511,137,0009,075,0003,809,0009,054,0002,678,0002,084,000
Net income
-6m
L-13.71%
-1,002,795-2,731,000-3,171,000-2,086,000574,000-14,288,000-5,078,000-7,456,000-6,434,000
CFO
-5m
L-54.50%
0-3,548,000-2,888,000-2,478,00018,970,000-13,051,000-12,586,000-11,831,000-5,383,000

Notes

No notes on this company yet
Write a private note on this company, for your eyes only

Profile

Aelis Farma S.A., a French biotechnology company founded in 2013 and headquartered in Bordeaux, is dedicated to the discovery and development of treatments for brain-related illnesses. The firm's research pipeline primarily focuses on signaling-specific inhibitors that target CB1 receptors. Its leading investigational drug, AEF0117, is currently advancing through Phase 2b clinical trials, designed to alleviate the harmful impacts of excessive cannabis consumption. Furthermore, AEF0217, another key drug candidate, has successfully completed Phase 1 clinical trials, with the goal of addressing cognitive impairments linked to Down syndrome and other similar conditions.

Key people

Pier Piazza
Chief Executive Officer, Director · since 2023
Sandy Fabre
Co-Founder, Head - Discovery and IP Leader
Marie Line Lafevre
Head - Finance
Stephanie Monlezun
Co-Founder, Chief Operating Officer
Lea Floquet
Head - Legal
Aurelie Boucard
Head - Preclinical Development
Corinne Chaimbault
Head - Pharmaceutical Development
Arsene Guekam
Chief Corporate Development Officer
Helle Mengel
Head - Clinical Development
M. Brahim Guetarni
Director, Representative of Nouvelle-Aquitaine Region · since 2021
Karina Hansen
Independent Director · since 2022
Independent Director · since 2022
Independent Chairman of the Board · since 2020
Independent Director · since 2022
IPO date
Feb 18, 2022
Employees
20
Domiciled in
FR
Incorporated in
FR
Headquarters & legal address
2 RUE ROBERT ESCARPIT
IECB
PESSAC 33600
FR

Valuation

Title
EUR in thousands, except ratios and share amounts
FYFYFYFYFYFYFYFYFY
2025‑122024‑122023‑122022‑122021‑122020‑122019‑122018‑122017‑12
Income
Revenues
Cost of revenue
Unusual Expense (Income)
NOPBT
NOPBT Margin
Operating Taxes
Tax Rate
NOPAT
Net income
Dividends
Dividend yield
Proceeds from repurchase of equity
BB yield
Debt
Debt current
Long-term debt
Deferred revenue
Other long-term liabilities
Net debt
Cash flow
Cash from operating activities
CAPEX
Cash from investing activities
Cash from financing activities
FCF
Balance
Cash
Long term investments
Excess cash
Stockholders' equity
Invested Capital
ROIC
ROCE
EV
Common stock shares outstanding
Price
Market cap
EV
EBITDA
EV/EBITDA
Interest
Interest/NOPBT